Despite a GAAP net loss, Ligand Pharmaceuticals Inc (LGND) showcases robust financial health and promising new ventures in ...

RBC Capital raised the firm’s price target on Ligand (LGND) to $155 from $143 and keeps an Outperform rating on the shares. The firm cites the ...

Reports Q4 revenue $42.8M, consensus $39.03M. “We achieved significant revenue growth in 2024 driven by strong momentum across our major ...

Capital will fund Castle Creek’s D-Fi Phase 3 clinical trial for patients with dystrophic epidermolysis bullosa through ...

Ligand Pharmaceuticals Incorporated ( NASDAQ: LGND) Q4 2024 Earnings Conference Call February 27, 2025 8:30 AM ET ...

Ligand Pharmaceuticals (NASDAQ:LGND – Get Free Report) is expected to announce its earnings results before the market opens ...

Ligand Pharmaceuticals (Nasdaq: LGND) has entered into a royalty financing agreement with Castle Creek Biosciences, providing ...

Novel protein cage systems can control and visualize orientational changes in aromatic side chains upon ligand binding, as ...

On a per-share basis, the Jupiter, Florida-based company said it had a loss of $1.64. The drugmaker posted revenue of $42.8 million in the period, which topped Street forecasts. Three analysts ...

Researchers from Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), Miramoon Pharma ...